Short description
Omega Ophthalmics’ intraocular lens increases the efficacy of cataract surgery and provides a space for in-eye technology, including AR/VR.
Description
Cataract surgery is the single most common procedure performed in the United States annually. Despite technological advancements in both surgical instrumentation and intraocular lens design, approximately 50% of patients are still unable to see well without glasses after surgery.
Omega Ophthalmics has developed a new, proprietary lens that will increase the number of “glasses free” post-surgery patients to over 90% by reducing the variables during surgery, revolutionizing a market that has not seen positive, disruptive change in over sixty years. Since the global intraocular lens market has steadily grown and is currently projected to reach $4.3 billion by 2017, the Omega Gemini Refractive Capsule is well-positioned to become the new standard lens for cataract surgery.
The Omega Gemini Refractive Capsule is an investigational device and is not approved for use in the United States.
Last funding
No Way
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Lexington, Kentucky, United States, North America
Founded on
January 1, 2013
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$34056 - 789030
Sign in for full access
Founders
Gary Wörtz, Rick Ifland